Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NVIV

InVivo Therapeutics (NVIV) Stock Price, News & Analysis

InVivo Therapeutics logo

About InVivo Therapeutics Stock (NASDAQ:NVIV)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.22
$0.79
52-Week Range
N/A
Volume
1.89 million shs
Average Volume
8.25 million shs
Market Capitalization
$997,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.

Remove Ads
Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Stock News Headlines

InVivo Therapeutics Holdings Co (NVIVQ)
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
InVivo Therapeutics Holdings Corp (NVIVQ)
InVivo Therapeutics Holdings Corporation
InVivo Therapeutics Holdings Corp.
See More Headlines

NVIV Stock Analysis - Frequently Asked Questions

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) announced its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($61.75) EPS for the quarter.

InVivo Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Tonix Pharmaceuticals (TNXP), Flexion Therapeutics (FLXN), OPKO Health (OPK), Acasti Pharma (ACST) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
5/13/2020
Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NVIV
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.48 per share
Price / Book
N/A

Miscellaneous

Free Float
3,029,000
Market Cap
$997,000.00
Optionable
Not Optionable
Beta
0.65

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:NVIV) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners